Company / Return on Equity (ROE)
Processa Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-44.8%
FY2022
5-year range
-254.1% / -44.8%
FY2018-FY2022
Trend
+28.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Processa Pharmaceuticals, Inc. reports negative total equity of -44.8% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-44.8% in FY2022.
Improved from -254.1% to -44.8% over the past 8 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, return on equity (roe) increased 28.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | -44.8% | +28.6% |
| FY2021 | -62.8% | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | -254.1% | -73.9% |
| FY2013 | -146.1% | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026